Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tabelecleucel + Pembrolizumab for EBV-Associated Nasopharyngeal Carcinoma
NCT03769467Phase 2Terminated
- Sponsor
- Atara Biotherapeutics
- Start
- Feb 2019
- Primary completion
- Aug 2021
- Modality
- Prophylactic Vaccines, Allogeneic CAR-T, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of tabelecleucel in nasopharyngeal carcinoma (NPC), sponsored by Atara Biotherapeutics. Started Feb 2019; status: terminated.
02
Drugs
tabelecleucel
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03769467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03769467.